化驗
99.95%
形狀
tubes
製造商／商標名
Goodfellow 479-740-56
電阻係數
10.6 μΩ-cm, 20°C
長度 × 壁厚
100 mm × 0.04 mm
外徑 × 內徑
0.5 mm × 0.42 mm
bp
3827 °C (lit.)
mp
1772 °C (lit.)
密度
21.45 g/cm3 (lit.)
SMILES 字串
[Pt]
InChI
1S/Pt
InChI 密鑰
BASFCYQUMIYNBI-UHFFFAOYSA-N
一般說明
For updated SDS information please visit www.goodfellow.com.
法律資訊
Product of Goodfellow
儲存類別代碼
13 - Non Combustible Solids
水污染物質分類（WGK）
nwg
閃點（°F）
Not applicable
閃點（°C）
Not applicable
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
Pei-Miao Li et al.
Ying yong sheng tai xue bao = The journal of applied ecology, 23(12), 3514-3525 (2013-03-14)
Anthropogenic platinum group elements (PGEs) are widely applied in vehicle exhaust catalytic converters (VECs), industrial catalysts, and pharmaceutics, making the PGEs, especially Pt, Pd, and Rh, become the newly environmental pollutants in some fields. Given the positive correlations between the
Fausto Petrelli et al.
Lung cancer (Amsterdam, Netherlands), 81(3), 337-342 (2013-07-31)
The sole agents pemetrexed (PEM), docetaxel and anti-EGFR agents are approved second-line therapies for non-small cell lung cancer (NSCLC) after failure with cisplatin-based doublets. The potential usefulness of platinum-based doublets as rechallenge for second-line chemotherapy has not yet been established.
Michele Iafisco et al.
Journal of inorganic biochemistry, 117, 237-247 (2012-07-25)
The present review focuses on the "drug targeting and delivery" approach of the selective transportation of cisplatin to bone tumors and bone metastases. This aim is realized by binding cisplatin to (bis)phosphonate ligands or their derivatives. Geminal bisphosphonates are in
Thorsten Langer et al.
Trends in pharmacological sciences, 34(8), 458-469 (2013-06-19)
Childhood cancer survival rates are now nearly 80% in more developed European countries because of improved therapies and better supportive care. Platinum chemotherapy drugs, such as cisplatin and carboplatin, are the cornerstone of many effective therapeutic protocols for childhood cancer.
Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer.
Himashinie V K Diyabalanage et al.
Cancer letters, 329(1), 1-8 (2012-10-04)
One of the most promising strategies to increase the efficacy of standard chemotherapy drugs is by combining them with low doses of histone deacetylases inhibitors (HDACis). Regarded as chemosensitizers, the addition of well-tolerated doses of HDACis to platinum-based chemotherapeutics has
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務